Wound healing is a highly orchestrated physiological process consisting of a complex events, and scarless wound healing is highly desired for the development and application in clinical medicine. Recently, we have demonstrated that human amniotic epithelial cells (hAECs) promoted wound healing and inhibited scar formation through a paracrine mechanism. However, exosomes (Exo) are one of the most important paracrine factors.
Watch Doc X’s latest interview with Invitrx on groundbreaking Stem Cell Therapy research.
#dentistry #oralhealth #teeth #dentalcare #dental #dentalhealth #oralcare #dentalclinic
Severe psoriasis, a chronic inflammatory skin disease is increasingly being effectively managed by targeted immunotherapy but long-term immunotherapy poses health risk and loss of response. Therefore, there is a need for alternative therapy strategies. Mesenchymal stem/stromal cell (MSC) exosomes are widely known for their potent immunomodulatory properties. Here we investigated if topically applied MSC exosomes could alleviate psoriasis-associated inflammation.
Exosomes, a specific subgroup of extracellular vesicles that are secreted by cells, have been recognized as
important mediators of intercellular communication. They participate in a diverse range of physiological
and pathological processes. Given the capability of exosomes to carry molecular cargos and transfer
bioactive components, exosome-based disease diagnosis and therapeutics have been extensively studied
over the past few decades. Herein, we highlight the emerging applications of exosomes.
The topical application of exosomes secreted by mesenchymal stem cells (MSC-Exos) on the skin is a very new and interesting topic in the medical field. In this study, we aimed to investigate whether marine sponge Haliclona sp. spicules (SHSs) could effectively enhance the skin delivery of human umbilical cord-derived MSC-Exos (hucMSC-Exos), and further evaluate the topical application of hucMSC-Exos combined with SHSs in rejuvenating photoaged mouse skin.
Baylx, Inc. (Baylx), a clinical-stage stem cell biopharmaceutical company focused on developing living stem cell products to address unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) cleared Baylx's Investigational New Drug (IND) application for BX-U001, a fresh, non-frozen human umbilical cord tissue mesenchymal stem cells (hUC-MSC) productin patients with COVID-19.
Mesenchymal stem cells (MSCs) have been shown to produce adenosine, express adenosine receptors, and communicate with macrophages and other cells. However, there is no information about the role of caffeine, as a popular drink and adenosine antagonist, on the crosstalk between MSCs and immune cells. The aim of the current study is to evaluate the effects of the conditioned medium of MSCs treated with caffeine on macrophages.
Exosomes are cell-derived membranous vesicles of endosomal origin secreted by all type of cells and present in
various body fuids. Exosomes are enriched in peptides, lipids, and nucleic acids, emerging as vital modulators in
intercellular communication. Exosomes are increasingly being evaluated as biomarkers for diagnosis and prognosis of
diseases, because the constituents of exosomes could be reprogrammed depending on the states of diseases. These
features also make exosomes a research hotspot.